NASDAQ · ASND
Ascendis Pharma A/S Ordinary Share
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ASND: Nov 11, 2026
Ascendis Pharma A/S Ordinary Share is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $1.13. The reported EPS for the same quarter last year was $-1.17.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.13 | $1.84 | $0.73 | 8 |
| Dec 2026 | $1.40 | $2.31 | $0.67 | 8 |
| Mar 2027 | $1.43 | $1.65 | $1.21 | 2 |
| Jun 2027 | $1.98 | $2.35 | $1.61 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · BNK Invest- Fintel · Oct 26, 4:23 PM EDTAscendis Pharma A/S Announces TransCon PTH Pooled Data Showing Kidney Function Improvements for Up to 5 YearsAscendis Pharma A/S announced new pooled data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) for up to 5 years. The results, derived from the Phase 2 PaTH
- RTTNews · Oct 26, 2:47 PM EDTAscendis Reports Sustained Kidney Function Improvements With TransCon PTH(RTTNews) – Ascendis Pharma A/S (ASND) reported pooled clinical data showing sustained improvements in kidney function among patients with hypoparathyroidism treated with TransCon PTH, according to findings presented at the 2026 American Society of Nephrology (ASN) Kidney Week.
- Zacks · Oct 7, 10:37 AM EDTFDA Grants Priority Review to BridgeBio's Dwarfism Drug FilingBBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
- BNK Invest · Sep 16, 12:52 PM EDTWednesday's ETF with Unusual Volume: PIEQThe Principal International Equity ETF is seeing unusually high volume in afternoon trading Wednesday, with over 421,000 shares traded versus three month average volume of about 34,000. Shares of PIEQ were up about 0.6% on the day. Components of that ETF with the highest volum
- Zacks · Sep 16, 12:01 PM EDTBioMarin Stops Voxzogo Development for Noonan SyndromeBMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.
- RTTNews · Sep 15, 1:08 AM EDTAscendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo Nordisk(RTTNews) – Ascendis Pharma (ASND), a commercial-stage biotechnology company, said its Board has authorised a share repurchase program of up to $400 million. Separately, the company will regain exclusive rights to develop, manufacture, and commercialise TransCon technology-based
- RTTNews · Sep 8, 3:26 AM EDTAscendis Pharma In Focus Ahead Of Infant Achondroplasia Data At ESPE Congress 2026(RTTNews) – Ascendis Pharma A/S (ASND), a commercial-stage biotechnology company, announced that it will share the latest data from its Endocrinology Rare Disease programs, including the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in
- RTTNews · Sep 4, 10:09 AM EDTWeekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) – This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring moves. Ionis, Milestone, Novavax advanced key programs, while United Imaging gaine
- Zacks · Sep 3, 12:28 PM EDTHow BioMarin Turned a Competitive Threat Into a Royalty-Bearing AssetBMRN turns a competitive threat into a royalty stream as Ascendis pays royalties on Yuviwel sales, reshaping the economics of competition.
- RTTNews · Aug 31, 11:27 AM EDTAscendis, BioMarin Enter Global Settlement, License Deal For YUVIWEL; Ascendis Stock Up(RTTNews) – Ascendis Pharma A/S (ASND) announced on Monday that it has entered into a binding term sheet with BioMarin Pharmaceutical Inc. (BMRN) for a global settlement and license agreement covering YUVIWEL (navepegritide) and related products.
- The Motley Fool · Aug 20, 9:29 AM EDTAscendis Pharma (ASND) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 13, 10:05 AM EDTAscendis Pharma A/S Q2 Earnings Call HighlightsCan BioMarin Stock Live Up to Wall Street’s High Expectations?Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to in
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Ascendis Pharma A/S Ordinary Share from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.